Biosynex SA

ALBIO.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBIO.PA stands at 22.6M. In comparison, BIM.PA has a market cap of 14B. Regarding current trading prices, ALBIO.PA is priced at €1.22, while BIM.PA trades at €119.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBIO.PA currently has a P/E ratio of -0.38, whereas BIM.PA's P/E ratio is 32.53. In terms of profitability, ALBIO.PA's ROE is -0.38%, compared to BIM.PA's ROE of +0.11%. Regarding short-term risk, ALBIO.PA is more volatile compared to BIM.PA. This indicates potentially higher risk in terms of short-term price fluctuations for ALBIO.PA.

ALBIO.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBIO.PA stands at 22.6M. In comparison, ERF.PA has a market cap of 10.8B. Regarding current trading prices, ALBIO.PA is priced at €1.22, while ERF.PA trades at €63.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBIO.PA currently has a P/E ratio of -0.38, whereas ERF.PA's P/E ratio is 29.46. In terms of profitability, ALBIO.PA's ROE is -0.38%, compared to ERF.PA's ROE of +0.05%. Regarding short-term risk, ALBIO.PA is less volatile compared to ERF.PA. This indicates potentially lower risk in terms of short-term price fluctuations for ALBIO.PA.

ALBIO.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBIO.PA stands at 22.6M. In comparison, LBIRD.PA has a market cap of 413.8M. Regarding current trading prices, ALBIO.PA is priced at €1.22, while LBIRD.PA trades at €18.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBIO.PA currently has a P/E ratio of -0.38, whereas LBIRD.PA's P/E ratio is 72.31. In terms of profitability, ALBIO.PA's ROE is -0.38%, compared to LBIRD.PA's ROE of +0.03%. Regarding short-term risk, ALBIO.PA is less volatile compared to LBIRD.PA. This indicates potentially lower risk in terms of short-term price fluctuations for ALBIO.PA.

ALBIO.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBIO.PA stands at 22.6M. In comparison, ALECR.PA has a market cap of 89.8M. Regarding current trading prices, ALBIO.PA is priced at €1.22, while ALECR.PA trades at €17,800.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBIO.PA currently has a P/E ratio of -0.38, whereas ALECR.PA's P/E ratio is 12.56. In terms of profitability, ALBIO.PA's ROE is -0.38%, compared to ALECR.PA's ROE of +0.10%. Regarding short-term risk, ALBIO.PA is more volatile compared to ALECR.PA. This indicates potentially higher risk in terms of short-term price fluctuations for ALBIO.PA.

ALBIO.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBIO.PA stands at 22.6M. In comparison, MDXH.BR has a market cap of 85.6M. Regarding current trading prices, ALBIO.PA is priced at €1.22, while MDXH.BR trades at €3.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBIO.PA currently has a P/E ratio of -0.38, whereas MDXH.BR's P/E ratio is -1.58. In terms of profitability, ALBIO.PA's ROE is -0.38%, compared to MDXH.BR's ROE of -1.79%. Regarding short-term risk, ALBIO.PA is less volatile compared to MDXH.BR. This indicates potentially lower risk in terms of short-term price fluctuations for ALBIO.PA.

ALBIO.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBIO.PA stands at 22.6M. In comparison, BCART.BR has a market cap of 27.2M. Regarding current trading prices, ALBIO.PA is priced at €1.22, while BCART.BR trades at €0.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBIO.PA currently has a P/E ratio of -0.38, whereas BCART.BR's P/E ratio is -0.32. In terms of profitability, ALBIO.PA's ROE is -0.38%, compared to BCART.BR's ROE of +2.04%. Regarding short-term risk, ALBIO.PA is more volatile compared to BCART.BR. This indicates potentially higher risk in terms of short-term price fluctuations for ALBIO.PA.

ALBIO.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBIO.PA stands at 22.6M. In comparison, ALPRE.PA has a market cap of 12.9M. Regarding current trading prices, ALBIO.PA is priced at €1.22, while ALPRE.PA trades at €3.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBIO.PA currently has a P/E ratio of -0.38, whereas ALPRE.PA's P/E ratio is -2.90. In terms of profitability, ALBIO.PA's ROE is -0.38%, compared to ALPRE.PA's ROE of +1.10%. Regarding short-term risk, ALBIO.PA is less volatile compared to ALPRE.PA. This indicates potentially lower risk in terms of short-term price fluctuations for ALBIO.PA.

ALBIO.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBIO.PA stands at 22.6M. In comparison, EEP.MC has a market cap of 6.3M. Regarding current trading prices, ALBIO.PA is priced at €1.22, while EEP.MC trades at €0.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBIO.PA currently has a P/E ratio of -0.38, whereas EEP.MC's P/E ratio is -54.00. In terms of profitability, ALBIO.PA's ROE is -0.38%, compared to EEP.MC's ROE of N/A. Regarding short-term risk, ALBIO.PA is less volatile compared to EEP.MC. This indicates potentially lower risk in terms of short-term price fluctuations for ALBIO.PA.

ALBIO.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBIO.PA stands at 22.6M. In comparison, MLAHC.PA has a market cap of 5.4M. Regarding current trading prices, ALBIO.PA is priced at €1.22, while MLAHC.PA trades at €0.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBIO.PA currently has a P/E ratio of -0.38, whereas MLAHC.PA's P/E ratio is -10.00. In terms of profitability, ALBIO.PA's ROE is -0.38%, compared to MLAHC.PA's ROE of N/A. Regarding short-term risk, ALBIO.PA is more volatile compared to MLAHC.PA. This indicates potentially higher risk in terms of short-term price fluctuations for ALBIO.PA.

ALBIO.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBIO.PA stands at 22.6M. In comparison, GV.PA has a market cap of 693.2K. Regarding current trading prices, ALBIO.PA is priced at €1.22, while GV.PA trades at €0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBIO.PA currently has a P/E ratio of -0.38, whereas GV.PA's P/E ratio is -0.02. In terms of profitability, ALBIO.PA's ROE is -0.38%, compared to GV.PA's ROE of -7.61%. Regarding short-term risk, ALBIO.PA is less volatile compared to GV.PA. This indicates potentially lower risk in terms of short-term price fluctuations for ALBIO.PA.